Supplementary Figure 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Roy S. Herbst(Smilow Cancer Hospital), Roshni Biswas(Dana-Farber Cancer Institute), Baili Zhang(The University of Texas MD Anderson Cancer Center), Jacob Geisberg(Harvard University), Dzifa Y. Duose(The University of Texas MD Anderson Cancer Center), Caddie Laberiano-Fernández(The University of Texas MD Anderson Cancer Center), Xingzhi Song(The University of Texas MD Anderson Cancer Center), Aashna Jhaveri(Dana-Farber Cancer Institute), Stephen Van Nostrand(Dana-Farber Cancer Institute), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Jennifer Altreuter(Dana-Farber Cancer Institute), Gheath Alatrash(Mayo Clinic), Edgar Gonzalez‐Kozlova(Icahn School of Medicine at Mount Sinai), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Rossana Lazcano(The University of Texas MD Anderson Cancer Center), Manishkumar Patel(Icahn School of Medicine at Mount Sinai), Joyce Yu(Dana-Farber Cancer Institute), Jocelyn Harris(Icahn School of Medicine at Mount Sinai), Mary W. Redman(Fred Hutch Cancer Center), Kimberly Argueta(Icahn School of Medicine at Mount Sinai), Seunghee Kim‐Schulze(Icahn School of Medicine at Mount Sinai), Len Taing(Dana-Farber Cancer Institute), Radim Moravec(Center for Cancer Research), Jiexin Zhang(The University of Texas MD Anderson Cancer Center), James Lindsay, Hsin-Hui Huang(Icahn School of Medicine at Mount Sinai), Mario L. Marques‐Piubelli(The University of Texas MD Anderson Cancer Center), Scott Gettinger(Yale Cancer Center), Ethan Cerami, Frank Rojas(The University of Texas MD Anderson Cancer Center), Rajyalakshmi Luthra, Hui Xie(Chengdu Organic Chemicals (China)), Karen Kelly(Cancer Research Center), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Gayatri Kumar(The University of Texas MD Anderson Cancer Center), Sacha Gnjatic(Tisch Hospital), Kasthuri Kannan(The University of Texas MD Anderson Cancer Center), James Provencher(Dana-Farber Cancer Institute), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), J. Jack Lee(The University of Texas MD Anderson Cancer Center), Hong Chen(Second Affiliated Hospital of Dalian Medical University), Kai Nie(Icahn School of Medicine at Mount Sinai), Jianhua Zhang(XinHua Hospital), Jhanelle E. Gray(Moffitt Cancer Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k